Sarcopenia: revised European consensus on definition and diagnosis

Alfonso J. Cruz-Jentoft*, Gulistan Bahat, Juergen Bauer, Yves Boirie, Olivier Bruyere, Tommy Cederholm, Cyrus Cooper, Francesco Landi, Yves Rolland, Avan Aihie Sayer, Stephane M. Schneider, Cornel C. Sieber, Eva Topinkova, Maurits Vandewoude, Marjolein Visser, Mauro Zamboni, Writing Group European Working Group, Extended Group EWGSOP2, Jos Schols

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3536 Citations (Web of Science)

Abstract

Background in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings.

Objectives to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia.

Recommendations sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia.

Conclusions EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.

Original languageEnglish
Pages (from-to)16-31
Number of pages16
JournalAge and Ageing
Volume48
Issue number1
DOIs
Publication statusPublished - Jan 2019

Keywords

  • sarcopenia
  • muscle strength
  • physical performance
  • muscle assessment
  • EWGSOP2
  • older people
  • SKELETAL-MUSCLE MASS
  • BIOELECTRICAL-IMPEDANCE ANALYSIS
  • OF-LIFE QUESTIONNAIRE
  • LOWER-EXTREMITY FUNCTION
  • ADIPOSE-TISSUE VOLUMES
  • DWELLING OLDER-PEOPLE
  • ALL-CAUSE MORTALITY
  • COMPUTED-TOMOGRAPHY
  • GRIP STRENGTH
  • GAIT SPEED

Cite this